Posts tagged BOPARAN
Boparan - comment

Once again, a rabbit from the hat arrives when Boparan is refinancing. The sale of the European business will reduce headline leverage to 2.7x. The new SSN is a £390m 5-year (NC2) deal on an Adjusted EBITDA of £141m and a margin of 6.4%. Margins of ~6.5% will likely be under pressure as supermarkets previously saw 5% as normal. In previous refinancings, pressure in the supply chain has followed quickly. We will take a proper look at the OM, but our bias is to look at Boparan as a short once the deal is done. 

Read More
Aengus McMahonBOPARAN
Boparan - comment

FY23 Q4 numbers were slightly above our expectations. Management is cautiously optimistic about margin improvement and resulting deleveraging in FY24. Boparan has managed this particular conjuring trick before when a refinance is imminent. It is also in

Read More
Aengus McMahonBOPARAN
Boparan – The magicians assistant

Please find our updated analysis here.

Boparan’s Q3 22/23 results were much better than expected, but our model still points to a challenging refinance process. The big question for Boparan’s refinancing is simple: can the company generate EBITDA >£120m whilst covering cash interest with

Read More